BiondVax Announces First Quarter 2020 Financial Results Jerusalem, Israel

First Quarter 2020 Financial Results

Jerusalem, Israel - June 30,

2020 - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing

and commercializing M-001, a universal influenza vaccine candidate, today announced its first quarter financial results for the

quarter ended March 31, 2020.

First Quarter 2020 Financial Summary

Results are in New Israel Shekels (NIS) and convenience

translation to $US is provided using the exchange rate of 3.57 (NIS/$US) as at March 31, 2020.

operating expenses for the first quarter were NIS 20.0 million (approximately $5.6 million) compared with NIS 7.1 million for

the first quarter of 2019.

increase in total operating expenses compared to the first quarter of 2019 was primarily due to expenses related to the ongoing

Phase 3 trial and scale-up at our manufacturing facility.

As of March 31, 2020, BiondVax had

cash and cash equivalents of NIS 42.5 million (approximately $11.9 million) compared to NIS 72.4 million as of December 31, 2019.

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical

stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide

multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary

technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the

immune system for a cross-protecting and long-lasting effect. In a total of seven completed Phase 1/2 and Phase 2 clinical trials

enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3

clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please

visit www.biondvax.com.

Joshua E. Phillipson | +972 8 930 2529

| j.phillipson@biondvax.com

Forward Looking Statements

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as

"expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements reflect the management's current views with respect to certain current and future events and are

subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by

the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, risks relating to the

COVID-19 (coronavirus) pandemic, the prosecution, timing and results of the ongoing Phase 2 and Phase 3 trials and any subsequent

trials; timing of receipt of regulatory approval of our manufacturing facility in Jerusalem; ability to demonstrate the efficacy

and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy

and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property

and patents granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis,

or at all, and receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy

of available cash resources and the ability to raise additional capital when needed. More detailed information about the risks

and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form

20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on

the SEC's website, www.sec.gov. We undertake no obligation to revise or update any forward-looking statement for any reason.

In thousands, except share and per share data

*) Represents less than NIS\USD 1.

STATEMENTS OF COMPREHENSIVE

In thousands, except share